Afghanistan

in page functions
[French]
Afghanistan
Total population (2017) 34,169,138
Birth cohort (2017) 1,083,160
Surviving Infants (surviving to 1 year per year, 2017) 1,013,596
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 66/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 91/1000
World Bank Index, IDA (2015) 2.69
Gross Nation Income (per capita US$, 2015) 610
Co-financing group (2018) Initial self-financing
No. of districts/territories (2016) 356

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Afghanistan

Type of support

Approvals

2001-2022 (US$)
(29 May 2018)

Commitments

2001-2022 (US$)
(29 May 2018)

Disbursements

2000-2018 (US$)
(29 May 2018)

% Disbursed

(29 May 2018)
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Total $317,472,224 $345,593,565 $297,869,044
Civil Society Organisation support (CSO) $3,561,578 $3,561,578 $3,877,478 109%
Health system strengthening (HSS 1) $34,100,000 $34,100,000 $34,100,000 100%
Health system strengthening (HSS 2) $17,727,209 $18,001,661 $16,469,963 93%
Health system strengthening (HSS 3) $38,117,610 $47,499,999 $20,539,953 54%
Immunisation services support (ISS) $14,025,300 $14,025,300 $14,025,300 100%
Injection Safety Devices (NVS) $1,659,500 $1,970,000 $1,945,276 117%
Injection safety support (INS) $1,676,500 $1,676,500 $1,676,500 100%
IPV (NVS) $4,099,901 $4,099,901 $3,501,801 85%
Measles SIA (NVS) $2,163,903 $2,163,903 $2,163,903 100%
Measles SIA - Operational costs (OPC) $3,574,000 $3,574,000 $3,574,000 100%
Measles-Follow-up campaign (NVS) $4,307,000 $4,307,000 $4,856,288 113%
Measles-Follow-up campaign op.costs (OPC) $8,702,377 $8,702,377
Penta (NVS) $70,372,886 $72,191,386 $69,852,566 99%
Pneumo (NVS) $94,191,604 $105,474,604 $103,614,366 110%
Product Switch Grant (PSG) $405,821 $405,821 $405,821 100%
Rotavirus (NVS) $5,393,500 $10,446,000 $3,872,294 72%
Tetra DTP-HepB (NVS) $9,903,633 $9,903,633 $9,903,633 100%
Vaccine Introduction Grant (VIG) $3,489,902 $3,489,902 $3,489,902 100%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Afghanistan DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2016)

Grade of confidence


N/A
DTP3 - Official country estimates (2016) 81%
M:F sex ratio at birth (2017) 1.06
Household survey: DTP3 coverage for male (2010) 41.60%
Household survey: DTP3 coverage for female (2010) 38.90%
Household survey: Last DTP3 survey (2010) 40%
% districts achieving > 80% DTP3 coverage (2016) 44%
% districts achieving < 50% DTP3 coverage (2016) 25%
MCV WHO/UNICEF estimates (2016) 62%

Breakdown of support

Non-vaccine support Vaccine support
33% 67%
$98,158,917 $199,710,127

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Afghanistan

07 June 2018

IPV DRC 2015

Gavi Board approves funding for inactivated poliovirus vaccine until 2020

Flexible support to Nigeria and post-transition countries also approved.

21 December 2017

2017 letter

2017: responding to global challenges

Letter from Gavi's CEO, Dr Seth Berkley.

24 October 2017

Bangladesh IPV PCV launch 2015

World Polio Day: Gavi's role in polio eradication

24 October marks World Polio Day, when the global community celebrates the immense progress and considers the work ahead to ensure no child suffers from polio again.

close icon

modal window here